Spots Global Cancer Trial Database for solid tumor, adult
Every month we try and update this database with for solid tumor, adult cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy | NCT05276284 | Solid Tumor, Ad... Metastatic Canc... | Atezolizumab, 6... | 18 Years - | Rigshospitalet, Denmark | |
| A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | NCT04328844 | Solid Tumor, Ad... Non-Hodgkin Lym... NSCLC Myelofibrosis Uveal Melanoma | IOA-244 Avelumab Inject... Pemetrexed Cisplatin Ruxolitinib | 18 Years - | iOnctura | |
| A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors | NCT05763004 | Solid Tumor, Ad... | IOS-1002 IOS-1002 + KEYT... | 18 Years - | ImmunOs Therapeutics AG | |
| MVX-ONCO-2 in Advanced Solid Tumors | NCT05071846 | Solid Tumor, Ad... | MVX-ONCO-2 | 18 Years - | Maxivax SA | |
| Clinical Study on the Treatment of Advanced Recurrent Tumors With Anticancer Mouse Characteristic Human Neutrophils | NCT06240767 | Solid Tumor, Ad... Advanced Cancer | Granulocyte inf... | 18 Years - 75 Years | Wuxi People's Hospital | |
| GPC3/Mesothelin-CAR-γδT Cells Against Cancers | NCT06196294 | Pancreas Cancer Lung Cancer Liver Cancer Mesothelioma CAR-T Cell Ther... Solid Tumor, Ad... | Cell therapy fo... | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| A Monotherapy in Subjects With Advanced Solid Tumors | NCT04221204 | Solid Tumor, Ad... | Highly selectiv... | 18 Years - | 3D Medicines | |
| Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors | NCT05559541 | Solid Tumor, Ad... | AK119 AK104 | 18 Years - | Akeso | |
| Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca | NCT03919292 | Solid Tumor, Ad... | Neratinib Divalproex Sodi... | 18 Years - | Virginia Commonwealth University | |
| First in Human, Dose Escalation, Dose Expansion Study of AUR105 | NCT05605119 | Solid Tumor, Ad... Non-hodgkin Lym... Hodgkin Lymphom... | AUR105 | 18 Years - 99 Years | Aurigene Discovery Technologies Limited | |
| 89Zr-labeled KN035 PET Imaging in Patients With PD-L1 Positive Solid Tumors | NCT04977128 | Solid Tumor, Ad... | 89Zr-KN035 | 18 Years - 75 Years | Wuxi No. 4 People's Hospital | |
| A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors | NCT05180799 | Solid Tumor, Ad... NSCLC Urothelial Carc... Gastric Cancer Small Cell Lung... Hepatocellular ... Cervical Carcin... Melanoma Renal Cell Carc... Carcinoma | BA3071 Nivolumab Pembrolizumab | 18 Years - | BioAtla, Inc. | |
| Effectiveness of Pharmacist Intervention on Capecitabine Relative Dose Intensity, Adherence, Knowledge & Safety Among Cancer Patients in Malaysia | NCT04175899 | Solid Tumor, Ad... | Pharmacist-led ... | 18 Years - | Ministry of Health, Malaysia | |
| New Formulation Study of Inupadenant (EOS100850) in Patients With Cancer | NCT05117177 | Solid Tumor, Ad... | Inupadenant | 18 Years - | iTeos Therapeutics | |
| PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies | NCT03030001 | Solid Tumor, Ad... Advanced Cancer | PD-1 antibody e... | 18 Years - 80 Years | Ningbo Cancer Hospital | |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer | NCT05216432 | PIK3CA Mutation Solid Tumor, Ad... HER2-negative B... Breast Cancer Metastatic Brea... Advanced Breast... Unresectable So... | RLY-2608 Fulvestrant Palbociclib 125... Ribociclib 400m... Ribociclib 600m... | 18 Years - | Relay Therapeutics, Inc. | |
| MUC1 Therapeutic Tumor Vaccine in Advanced Solid Cancers | NCT05986981 | Solid Tumor, Ad... | Vaccine | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors | NCT05074472 | Solid Tumor, Ad... Pancreatic Duct... Ovarian Serous ... Biliary Cancer ... Ovarian Serous ... | ZB131 | 18 Years - | ZielBio, Inc. | |
| IMX-110 in Patients With Advanced Solid Tumors | NCT03382340 | Solid Tumor, Ad... Advanced Solid ... Pancreatic Canc... Breast Cancer Ovarian Cancer | Imx-110 | 18 Years - | Immix Biopharma, Inc. | |
| Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs | NCT04770207 | Hepatocellular ... Solid Tumor, Ad... | Injection of dr... | 18 Years - 99 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| A Study of HQP1351 in Patients With GIST or Other Solid Tumors | NCT03594422 | Gastrointestina... Solid Tumor, Ad... | HQP1351 | 12 Years - | Ascentage Pharma Group Inc. | |
| A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours | NCT02977364 | Carcinoma Solid Tumor, Ad... | HS-10241 | 18 Years - 65 Years | Jiangsu Hansoh Pharmaceutical Co., Ltd. | |
| A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors | NCT06433726 | Solid Tumor, Ad... | BY101921 tablet... | 18 Years - 75 Years | Chengdu Baiyu Pharmaceutical Co., Ltd. | |
| U87 CART in Treatment of Advanced Solid Tumor | NCT05605197 | Pancreatic Canc... Solid Tumor, Ad... | U87 CAR-T | 18 Years - 75 Years | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | |
| A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | NCT04328844 | Solid Tumor, Ad... Non-Hodgkin Lym... NSCLC Myelofibrosis Uveal Melanoma | IOA-244 Avelumab Inject... Pemetrexed Cisplatin Ruxolitinib | 18 Years - | iOnctura | |
| Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors | NCT05689853 | Solid Tumor, Ad... | AK119 AK112 | 18 Years - 75 Years | Akeso | |
| A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies | NCT03922204 | Advanced Cancer Solid Tumor, Ad... B-cell Lymphoma... | MCLA-145 | 18 Years - | Merus N.V. | |
| Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects | NCT06348290 | Solid Tumor, Ad... | JMKX001899 Itraconazole Midazolam Rifampin dextromethorpha... Rosuvastatin digoxin | 18 Years - 45 Years | Jemincare | |
| A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | NCT06265727 | Solid Tumor, Ad... | CRB-701 | 18 Years - | Corbus Pharmaceuticals Inc. | |
| Circulating Tumor DNA as Liquid Biopsy in Patients With Stage IV Solid Tumors, a Feasibility Study at MUSC HCC | NCT03302325 | Solid Tumor, Ad... | research blood ... | 18 Years - | Medical University of South Carolina | |
| Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors | NCT04556669 | Solid Tumor, Ad... Cervical Cancer Sarcoma NSCLC | Autologous aPD-... | 18 Years - 75 Years | Hebei Senlang Biotechnology Inc., Ltd. | |
| A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | NCT06228326 | Lung Cancer, No... Lung Cancer Met... Solid Tumor, Ad... Advanced Cancer Lung Cancer, Sm... Metastatic Colo... Metastatic Rena... Metastatic Hepa... Metastatic Sarc... Metastatic Oste... | KB707 | 18 Years - | Krystal Biotech, Inc. | |
| IMX-110 in Patients With Advanced Solid Tumors | NCT03382340 | Solid Tumor, Ad... Advanced Solid ... Pancreatic Canc... Breast Cancer Ovarian Cancer | Imx-110 | 18 Years - | Immix Biopharma, Inc. | |
| GT201 Injection For The Treatment Of Advanced Solid Tumors | NCT06144671 | Solid Tumor, Ad... | GT201 | 18 Years - 70 Years | Grit Biotechnology | |
| CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors | NCT05947487 | Solid Tumor, Ad... | CD70-targeting ... | 18 Years - 75 Years | Chinese PLA General Hospital | |
| Personalized Models for Cancer Research | NCT06350539 | Solid Tumor, Ad... | Biological Samp... | 18 Years - | New York Stem Cell Foundation Research Institute | |
| Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma | NCT03465592 | Sarcoma Solid Tumor, Ad... Solid Tumor, Ch... | Nivolumab | 12 Months - 40 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression | NCT04927663 | Castration-Resi... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... Solid Tumor, Ad... Solid Tumor Metastatic Cast... | Computed Tomogr... Magnetic Resona... Positron Emissi... 11C-YJH08 Optional Tumor ... | 18 Years - | University of California, San Francisco | |
| Expanded Access Neoantigen Vaccine in Solid Tumors | NCT03914872 | Solid Tumor, Ad... | Neoantigen DNA ... Integrated elec... | 18 Years - | Washington University School of Medicine | |
| Feasibility of a Process of Digital Validation of Chemotherapies in a Day Treatment Unit | NCT03977766 | Solid Tumor, Ad... | Chemotherapy pr... | 18 Years - 80 Years | Institut Paoli-Calmettes | |
| Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients. | NCT04739696 | Breast Cancer Lung Cancer Colon Cancer Solid Tumor, Ad... | PEPRR Pep-Pal | 18 Years - 64 Years | University of Colorado, Denver | |
| A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors | NCT05763004 | Solid Tumor, Ad... | IOS-1002 IOS-1002 + KEYT... | 18 Years - | ImmunOs Therapeutics AG | |
| First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors | NCT05054348 | Solid Tumor, Ad... | IO-108 IO-108 + pembro... IO-108 + cemipl... | 18 Years - | Immune-Onc Therapeutics | |
| Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent | NCT06075849 | Solid Tumor, Ad... Solid Tumor Gastric Cancer Hepatocellular ... Metastatic Colo... Advanced Solid ... | PB101 | 19 Years - | Panolos Bioscience | |
| PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | NCT03149549 | Solid Tumor, Ad... Breast Cancer Non Small Cell ... Head and Neck C... Ovarian Cancer | CX-2009 | 18 Years - | CytomX Therapeutics | |
| Safety Study of 177Lu-Anti-ED-B mAbs SPECT Imaging in Patients With ED-B Positive Solid Tumors | NCT05623891 | Solid Tumor, Ad... | 177Lu-B5-IgG4 | 18 Years - 75 Years | Affiliated Hospital of Jiangnan University | |
| Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | NCT05856981 | Solid Tumor, Ad... Metastatic Soli... Refractory Canc... | ADU-1805 Pembrolizumab | 18 Years - | Sairopa B.V. | |
| A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | NCT04913285 | Solid Tumor, Ad... Non-small Cell ... Melanoma | KIN-2787 KIN-2787 and bi... | 18 Years - | Pierre Fabre Medicament | |
| Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors | NCT04053673 | Solid Tumor, Ad... | RBN-2397 | 18 Years - | Ribon Therapeutics, Inc. | |
| Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors | NCT04165772 | Rectal Adenocar... Clinical Stage:... Stage III (Any ... Solid Tumor Solid Tumor, Ad... | TSR-042 or Dost... capecitabine or... Intensity Modul... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of HB0045 Injection in Patients With Advanced Solid Tumors | NCT06056323 | Solid Tumor, Ad... | HB0045 Drug Pro... | 18 Years - | Shanghai Huaota Biopharmaceutical Co., Ltd. | |
| Systematic Evaluation of Human Explant Model Systems Engineering | NCT04671654 | Solid Tumor, Ad... | 18 Years - | University Hospital Heidelberg | ||
| A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody | NCT05662397 | Solid Tumor, Ad... Relapsed Cancer Refractory Canc... | HST-1011 Cemiplimab | 18 Years - | HotSpot Therapeutics, Inc | |
| A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib | NCT04814667 | Solid Tumor, Ad... Locally Advance... Metastatic Canc... | 25 Years - | Centre Leon Berard | ||
| Improving Cyberknife Spinal Stereotactic Radiotherapy in Difficult to Treat Cases (IMPRESS) | NCT05252975 | Solid Tumor, Ad... | Setup and Imagi... | 18 Years - | Royal Marsden NHS Foundation Trust | |
| 18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR | NCT02717572 | Solid Tumor, Ad... | Fludeoxyglucose... Positron Emissi... Computerized To... Magnetic Resona... | 18 Years - | Washington University School of Medicine | |
| Safety and Efficacy Study of IMSA101 in Refractory Malignancies | NCT04020185 | Solid Tumor, Ad... | IMSA101 Immune checkpoi... Immuno-oncology... | 18 Years - | ImmuneSensor Therapeutics Inc. | |
| Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors | NCT05055609 | Solid Tumor, Ad... Oncology | TRE-515 | 18 Years - | Trethera | |
| A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors | NCT05866692 | Solid Tumor, Ad... | TY-2699a | 18 Years - | TYK Medicines, Inc | |
| Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects | NCT06348290 | Solid Tumor, Ad... | JMKX001899 Itraconazole Midazolam Rifampin dextromethorpha... Rosuvastatin digoxin | 18 Years - 45 Years | Jemincare | |
| GT201 Injection For The Treatment Of Advanced Solid Tumors | NCT06144671 | Solid Tumor, Ad... | GT201 | 18 Years - 70 Years | Grit Biotechnology | |
| POA Retrospective Repository | NCT03326479 | Oncology Solid Tumor, Ad... | Caris Molecular... | 18 Years - | Caris Science, Inc. | |
| Stratification of Patients in Oncogeriatrics and Personalization of Interventions | NCT05131113 | Oncology Solid Tumor, Ad... | Physical exerci... | 70 Years - 100 Years | Biogipuzkoa Health Research Institute | |
| IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors | NCT05958121 | Refractory Canc... Recurrent Cance... Solid Tumor, Ad... Cancer | IMA402 (Phase I... IMA402 (Phase I... IMA402 (Phase I... | 18 Years - | Immatics Biotechnologies GmbH | |
| A Beta-only IL-2 ImmunoTherapY Study | NCT05086692 | Advanced Solid ... Unresectable So... Clear Cell Rena... Triple Negative... Non-Small Cell ... Non-Small Cell ... Colorectal Canc... Gastric Cancer Cervical Cancer Basal Cell Carc... Bladder Cancer Merkel Cell Car... Squamous Cell C... Cutaneous Squam... Pleural Mesothe... Esophageal Canc... Endometrial Car... Solid Tumor Solid Tumor, Ad... MSI-H Solid Mal... Cancer With A H... Epithelial Ovar... Primary Periton... Gastroesophagea... Acral Melanoma Mucosal Melanom... Cutaneous Melan... DMMR Solid Mali... Fallopian Tube ... Ovarian Cancer MSI-H Cancer DMMR Cancer Pancreas Adenoc... Skin Cancer | MDNA11 Pembrolizumab | 18 Years - | Medicenna Therapeutics, Inc. | |
| A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies | NCT04014257 | Phase 1 Solid Tumor, Ad... | NOV1601(CHC2014... | 19 Years - | Handok Inc. | |
| Ex Vivo Tumor Visualization and Resection Margin Assessment Using Topically Applied Fluorescent Imaging Agents | NCT06292845 | Solid Tumor, Ad... | Topical applica... | 18 Years - | Erasmus Medical Center | |
| Improving Cyberknife Spinal Stereotactic Radiotherapy in Difficult to Treat Cases (IMPRESS) | NCT05252975 | Solid Tumor, Ad... | Setup and Imagi... | 18 Years - | Royal Marsden NHS Foundation Trust | |
| A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects. | NCT04428086 | Solid Tumor, Ad... | Apatinib in arm... Rosuvastatin Apatinib in arm... Metformin | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors | NCT04901806 | Solid Tumor, Ad... Brain Tumor, Pr... Desmoplastic Sm... | PBI-200 | 18 Years - | Pyramid Biosciences | |
| Perfusion-Induced Hyperthermia for Metastatic Carcinoma | NCT02409108 | Metastatic Non-... Solid Tumor, Ad... | Exatherm-TBH sy... | 22 Years - | University of Kentucky | |
| A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial | NCT06026254 | Solid Tumor, Ad... | IMSA101 Immune Checkpoi... | 18 Years - | ImmuneSensor Therapeutics Inc. | |
| Intravital Microscopy in Human Solid Tumors | NCT03823144 | Solid Tumor, Ad... Clinical Stage ... Gastric Carcino... Malignant Solid... Metastatic Colo... Metastatic Gast... Metastatic Prim... Metastatic Sarc... Postneoadjuvant... Resectable Colo... Resectable Live... Resectable Panc... Resectable Sarc... Stage IV Colore... | Diagnostic Micr... Fluorescein Sod... | 18 Years - | Mayo Clinic | |
| A Study of AK-01 (LY3295668) in Solid Tumors | NCT03092934 | Neoplasms Neoplasm Metast... Triple Negative... Head and Neck N... Breast Neoplasm... Solid Tumor, Ad... Small Cell Lung... | LY3295668 | 18 Years - | Eli Lilly and Company | |
| 89Zr-KN035 PET Imaging in Patients With Advanced Solid Tumors | NCT03638804 | Solid Tumor, Ad... | 89Zr-KN035 | 18 Years - 75 Years | The First Affiliated Hospital of Soochow University | |
| Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors | NCT03905148 | Solid Tumor, Ad... | Lifirafenib mirdametinib | 18 Years - | BeiGene | |
| AVID100 in Advanced Epithelial Carcinomas | NCT03094169 | Solid Tumor, Ad... Triple Negative... Head and Neck S... Non Small Cell ... | AVID100 IV | 18 Years - | Formation Biologics | |
| A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors | NCT05763004 | Solid Tumor, Ad... | IOS-1002 IOS-1002 + KEYT... | 18 Years - | ImmunOs Therapeutics AG | |
| Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors | NCT05307874 | Solid Tumor, Ad... | ICT01 Proleukin Injec... Pembrolizumab i... | 18 Years - | ImCheck Therapeutics | |
| Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 Monotherapy in Advanced Solid Tumors | NCT06088004 | Solid Tumor, Ad... | ABO2011 Injecti... | 18 Years - | Suzhou Abogen Biosciences Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
